Company intelligence / Profile preview
Northern Therapeutics
- Ownership
- Private
- Employees
- ~6
- Development stage
- Other
Overview
Northern Therapeutics has developed and tested cell and gene therapies targeting pulmonary diseases, notably pulmonary arterial hypertension. Their nitric oxide synthase-based therapies have reached early clinical development, with at least one program discontinued and others pending further advancement. The company has also filed patents for cell-based therapies for the pulmonary system. A first-in-human trial of a related product in critically ill patients showed favorable tolerability and safety.
- Therapeutic areas
- Infectious DiseasesCardiovascular
- Modalities
- Gene therapyCell therapyAutologous cell-based gene therapyNitric oxide synthase gene therapy
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Northern Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Northern Therapeutics.